Plain-English translation of NCT06631287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help people who are still struggling with long-term effects of COVID-19. Many people experience persistent brain fog, memory problems, shortness of breath, and fatigue for months or even years after their initial COVID infection, and right now there are no proven treatments. This study will see whether this medication can improve these lingering symptoms.
Millions of people worldwide are suffering from long-term COVID symptoms that seriously affect their daily lives and ability to work, yet no effective treatments exist. Researchers believe this medication may help reduce the inflammation in the brain and body that causes these persistent symptoms.
You likely qualify if…
You likely don't qualify if…
If you are selected for this study, you will be randomly assigned to either take the medication or a placebo (inactive pill) every day for several months. You will have regular visits with the study team where they will check how you are doing, perform some physical and cognitive tests, and monitor you for any side effects. The study involves about 550 participants across multiple locations, and your participation helps researchers understand whether this treatment can help people recover from long-term COVID symptoms.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United States